Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027

Oncopeptides AB ( (SE:ONCO) ) has shared an announcement.

Oncopeptides reported that unaudited net sales reached 18.6 million SEK in the fourth quarter of 2025, up 88% year-on-year, while full-year 2025 Pepaxti sales climbed 125% to 71.2 million SEK, driven by a stronger-than-expected launch in Italy but partly offset by weaker uptake in Germany and strike-related headwinds in Spain. The company now anticipates achieving positive cash flow in 2027 instead of late 2026 and is tightening its commercialization strategy in Germany, pursuing a potential licensing deal for Pepaxti in Japan with a sizeable local pharma partner, and exploring additional European opportunities and pipeline partnerships, moves that signal a push to strengthen its financial position and broaden its international footprint despite near-term commercial challenges.

The most recent analyst rating on (SE:ONCO) stock is a Buy with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.

More about Oncopeptides AB

Oncopeptides AB is a Swedish biotechnology company specializing in targeted therapies for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate (PDC) and SPiKE platforms to deliver cytotoxic agents selectively into cancer cells. Its flagship oncology drug Pepaxti is being commercialized in Europe, complemented by partnership agreements in regions including South Korea, the Middle East and Africa, and the company operates with around 80 employees across Sweden, Germany, Austria, Spain and Italy, with its shares listed on Nasdaq Stockholm under the ticker ONCO.

Average Trading Volume: 1,903,867

Technical Sentiment Signal: Hold

Current Market Cap: SEK1.14B

For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.